Eterna Therapeutics Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The supplied filing identifies the registrant as Eterna Therapeutics Inc. (Nasdaq: ERNA), not “Ernexa Therapeutics Inc.” Eterna is a preclinical life-sciences company focused on licensing its mRNA cell-engineering technology platform; management says it is not currently developing product candidates.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | $47,000 | None |
| Cost of revenue / gross loss | $61,000 / $(14,000) | $50,000 / $(50,000) |
| Research and development | $1.458 million | $1.674 million |
| General and administrative | $4.315 million | $3.592 million |
| Operating loss | $(5.787) million | $(5.316) million |
| Net loss | $(6.647) million | $(5.416) million |
| Net loss per share, basic and diluted | $(1.23) | $(1.06) |
| Cash used in operations | $3.747 million | $6.049 million |
- Revenue came from cell-line customization work for Lineage; it was recognized over an expected 20–25-month development period. Additional contractual consideration remains subject to progress and revenue-recognition constraints.
- Cash and cash equivalents were $5.116 million at March 31; an additional $4.095 million was restricted as collateral for the Somerville facility letter of credit. Combined cash, cash equivalents and restricted cash were $9.211 million.
- Total liabilities were $53.069 million, including $39.439 million in operating lease liabilities. Stockholders’ equity was a deficit of $3.412 million; accumulated deficit was $193.628 million.
- Convertible notes had $18.198 million gross principal at quarter-end and a net balance-sheet carrying value of $8.014 million after debt discount and issuance costs. The company reported approximately $18.5 million outstanding, including paid-in-kind interest, as of the report date. Notes bear 6% or 12% interest, mature five years after issuance, and are convertible at specified prices; none had converted by March 31.
Material changes and management commentary
- Net loss increased $1.231 million year over year. Higher G&A, particularly occupancy costs associated with the Somerville sublease, and approximately $0.8 million of note-related interest expense drove the increase; R&D expense declined $0.216 million.
- Management concluded there is substantial doubt about the company’s ability to continue as a going concern: it does not expect available cash or working capital to fund operations for the 12 months following issuance of the financial statements. Additional capital is needed, and management gives no assurance it can be raised on acceptable terms or at all. The SEPA provides for up to $10 million of potential stock purchases, but only about $0.3 million had been raised through it to date; no shares were sold under it in Q1.
- Management’s near-term plan is to seek revenue through IP out-licensing or partnerships and pursue selected preclinical work. Longer-term plans include progressing toward clinical development, but the filing provides no quantified financial or operational guidance.
Risks, contingencies and unusual items
- Somerville rent and default exposure: The company had not paid rent for February through May 2024 and reported approximately $2.3 million past due, plus about $70,000 in late fees and interest. After a May 3 notice, it did not pay within the stated five-business-day period while discussing remedies and possible lease renegotiation. The sublessor had not drawn on the $4.1 million letter of credit as of filing. A sublease default could have further consequences, including potential cross-default exposure under the convertible notes. The remaining lease commitment is substantial; management estimates roughly $61.7 million of base rent over the remaining term, plus other charges.
- Potential dilution: At March 31, 20.386 million warrants were outstanding. Another 30.436 million potential common shares—including warrants, notes, options, preferred stock and RSUs—were excluded from diluted loss per share as anti-dilutive, compared with 5.410 million common shares outstanding. The CEO received an option for approximately 1.685 million shares.
- Internal controls: Management found disclosure controls ineffective at quarter-end due to an unremediated material weakness involving technical accounting proficiency and review of complex transactions. Remediation efforts are ongoing and have not yet operated long enough for management to conclude the weakness is remediated.
- Listing risk: The filing describes a Nasdaq minimum-equity compliance notice and possible delisting if compliance is not regained. Its reference to equity as of December 31, 2024 appears inconsistent with this Q1 2024 filing and should be checked against the original disclosure.
- Legal and other items: A trademark dispute was settled, with the company planning to phase out its current ETERNA trademark use by October 31, 2024. Separate litigation involving former Novellus employees remained ongoing; any future legal advancement or reimbursement was not considered probable or reasonably estimable. Changes in warrant fair value caused a $70,000 noncash expense in Q1.
Important facts for investors to verify
- Current cash runway, financing plans and whether additional capital has been secured since the filing.
- Whether the Somerville lease default was cured or renegotiated, whether the letter of credit was drawn, and any resulting note-default implications.
- The status of Nasdaq’s equity-compliance process and the filing’s apparently inconsistent December 31, 2024 date.
- Convertible-note terms, accrued interest, potential conversion and warrant dilution relative to the small common-share base.
- Progress in remediating the material weakness and any subsequent changes to controls or reporting reliability.
- Whether Lineage exercises its option or cell-line work generates further revenue; current revenue remains limited and the company reports no active product-candidate development.